We simulated four therapeutic scenarios to evaluate immune and tumor responses in a highly immunosuppressive TME: (1) Treg-enriched baseline, (2) Treg-targeted monotherapy, (3) PD-1 blockade monotherapy, and (4) Combination therapy. Here, PDCD1 is linked to neoplasm.